Defiance ETFs introduces 5 new leveraged ETFs providing magnified exposure to popular tech, healthcare, and retail stocks, with a mix of growth and income.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.4% in the afternoon session after investors took some profits off the table as markets awaited signals on future monetary policy from the Federal Reserve's Jackson Hole symposium later in the week.
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects next quarter’s revenue to be around $580 million, close to analysts’ estimates. Its non-GAAP profit of $0.29 per share was 26.3% above analysts’ consensus estimates.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the disclosure of significant stock sales by top executives, including CEO Andrew Dudum. According to SEC filings, CEO Andrew Dudum sold 660,000 shares for a total of approximately $33.4 million. The selling was not limited to the CEO, as Chief Medical Officer Patrick Carroll also sold 60,000 shares valued at around $3.2 million, while the company's chief commercial officer also recently parted with shares. Such significant stock sales by a company's top leadership can raise concerns among investors about the firm's future prospects. These transactions come at a challenging time for the telehealth company, which has recently faced legal pressure from drugmaker Novo Nordisk and a class-action lawsuit related to its compounded weight-loss drug offerings.
Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases.
Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales
Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks involved in this insightful analysis.
